In ovarian and breast cancer, promoter methylation of BRCA1 or RAD51C is a promising biomarker for PARP inhibitor response, as high levels lead to homologous recombination deficiency (HRD). This evidence concerns the gene BRCA1 and hypoparathyroidism-retardation-dysmorphism syndrome.